Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups (Q74616021)
Jump to navigation
Jump to search
scientific article published on 01 February 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups |
scientific article published on 01 February 1999 |
Statements
Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups (English)
H Ekberg
L Bäckman
G Tufveson
1 February 1999